Rapport Therapeutics, Inc. Common Stock (RAPP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
99 High Street
Boston, MA 02110
United States of America (the)
Phone
+1 617 945 0548
Website
Sector
Healthcare
Industry
Biotechnology
Employees
84
First IPO Date
June 07, 2024
| Name | Title | Pay | Year Born |
| Abraham N. Ceesay | Chief Executive Officer, President, Treasurer & Director | 1.11M | 1978 |
| Steven Paul | Founder & Independent Chairman | 44,000 | 1951 |
| Cheryl Gault | Chief Operating Officer | 281,110 | 1980 |
| Troy A. Ignelzi | Chief Financial Officer | 795,366 | 1968 |
| Jeffrey Sevigny | Chief Medical Officer | 1.04M | 1970 |
| Julie DiCarlo | Head of Communications & Investor Relations | 0 | N/A |
| Karina Chmielewski | Chief Information Officer & Head of Operations | 0 | N/A |
| David Bredt | Founder & Chief Scientific Officer | 0 | 1966 |
| Kathleen A. Wilkinson | Chief People Officer | 0 | 1972 |
| Swamy Yeleswaram | Chief Development Officer | 0 | 1964 |
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.